Anticardiolipin and anti-β2-glycoprotein-I antibodies in preeclampsia

被引:46
作者
Lee, RM
Brown, MA
Branch, DW
Ward, K
Silver, RM
机构
[1] Univ Utah, Med Ctr, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA
[2] Phoenix Perinatal Associates, Obstetrix Med Grp, Phoenix, AZ USA
关键词
D O I
10.1016/S0029-7844(03)00477-0
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To estimate whether antiphospholipid antibodies, specifically anticardiolipin and anti-beta(2)-glycoprotein-I antibodies, are associated with preeclampsia. METHODS: Plasma was prospectively obtained from four groups of pregnant women: those with 1).mild preeclampsia (n = 109); 2) severe preeclampsia (n = 134); 3) hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome (n = 57); and 4) normotensive controls (n = 100). Anticardiolipin and anti-beta(2)-glycoprotein-I levels were determined by enzyme-linked immunoassay. RESULTS: Subjects with mild preeclampsia, severe preeclampsia, and HELLP syndrome did not have significantly elevated levels of immunoglobulin G (IgG) and IgM anticardiolipin and anti-beta(2)-glycoprotein-I antibodies compared with normotensive controls (P > .05, Kruskal-Wallis). Similarly, subjects with mild preeclampsia, severe preeclampsia, and HELLP syndrome did not have a significantly higher proportion of women testing positive for each autoantibody compared with normotensive controls (chi(2)). The proportion of patients testing positive for anticardiolipin and anti-beta(2)-glycoprotein-I antibodies were similar in patients with preeclampsia developing before and after 34 weeks' gestation (chi(2)). CONCLUSION: Circulating levels of both anticardiolipin and anti-beta(2)-glycoprotein-I antibodies were not increased in patients with mild preeclampsia, severe preeclampsia, or HELLP syndrome compared with normotensive controls. Our data do not support routine testing for anticardiolipin and anti-beta(2)-glycoprotein-I antibodies in women with preeclampsia.
引用
收藏
页码:294 / 300
页数:7
相关论文
共 36 条
[1]  
ACOG Committee on Obstetric Practice, 2002, Int J Gynaecol Obstet, V77, P67
[2]   A United States national reference for fetal growth [J].
Alexander, GR ;
Himes, JH ;
Kaufman, RB ;
Mor, J ;
Kogan, M .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (02) :163-168
[3]  
Allen JY, 1996, AM J REPROD IMMUNOL, V36, P81
[4]  
BRANCH DW, 1989, OBSTET GYNECOL, V73, P541
[5]   Antiphospholipid antibodies in women at risk for preeclampsia [J].
Branch, DW ;
Porter, TF ;
Rittenhouse, L ;
Caritis, S ;
Sibai, B ;
Hogg, B ;
Lindheimer, MD ;
Klebanoff, M ;
MacPherson, C ;
VanDorsten, JP ;
Landon, M ;
Paul, R ;
Miodovnik, M ;
Meis, P ;
Thurnau, G .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (05) :825-832
[6]  
BRANCH DW, 1992, OBSTET GYNECOL, V80, P614
[7]  
CABIEDES J, 1995, J RHEUMATOL, V22, P1899
[8]  
D'Anna R., 1997, Clinical and Experimental Obstetrics and Gynecology, V24, P135
[9]   UNDERLYING DISORDERS ASSOCIATED WITH SEVERE EARLY-ONSET PREECLAMPSIA [J].
DEKKER, GA ;
DEVRIES, JIP ;
DOELITZSCH, PM ;
HUIJGENS, PC ;
VONBLOMBERG, BME ;
JAKOBS, C ;
VANGEIJN, HP .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 173 (04) :1042-1048
[10]   Antiphospholipid antibodies and preeclampsia: A case-control study [J].
Dreyfus, M ;
Hedelin, G ;
Kutnahorsky, R ;
Lehmann, M ;
Viville, B ;
Langer, B ;
Fleury, A ;
M'Barek, M ;
Treisser, A ;
Wiesel, ML ;
Pasquali, JL .
OBSTETRICS AND GYNECOLOGY, 2001, 97 (01) :29-34